Immunotherapy: Clinical Trials

22 trials for Immunotherapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

22 completed. 22 Phase 2, 4 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 222Completed 22
Phase 14Completed 4
Phase 32Completed 2

Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
Tislelizumab, Afatinib, Low dose radiotherapy - Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy
Phase 2CompletedWest China Hospital982025-06-282026-06-30
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
lorigerlimab, docetaxel, Prednisone - Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms
Phase 2CompletedMacroGenics1542023-09-282026-05-22
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma
Pembrolizumab, Encorafenib, Binimetinib - Malignant Melanoma, Metastatic Melanoma
Phase 2CompletedDr. Ronnie Shapira12023-09-052025-07-22
Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases
Serplulimab combined with bevacizumab and first-line chemotherapy - Non-small Cell Lung Cancer Stage II, Bevacizumab
Phase 2 / Phase 3CompletedSun Yat-sen University402023-05-142024-11-13
Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)
Serplulimab and Chemotherapy - Non-small Cell Lung Cancer, Stage II-IIIA
Phase 2CompletedFudan University302023-03-152025-10-01
Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer
xintilimab injection, Control - Neoadjuvant Chemoradiation Therapy, Rectal Cancer
Phase 2 / Phase 3CompletedChanghai Hospital2012022-10-012026-01-02
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Terelizumab (aka Tislelizumab), CapeOx, Trastuzumab - Immunotherapy, Gastric Cancer
Phase 2CompletedDaping Hospital and the Research Institute of Surgery of the Third Military Medical University1892022-09-012026-04-01
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Tislelizumab, Apatinib Mesylate, oxaliplatin - Immunotherapy, Gastrict Cancer
Phase 2CompletedFujian Cancer Hospital402021-10-312025-03-18
Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma
Tislelizumab in combination with anlotinib - Pulmonary Pleomorphic Carcinoma, Immunotherapy
Phase 2CompletedSecond Affiliated Hospital of Nanchang University292021-08-172026-05-28
mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC
mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations - Colorectal Cancer, Immunotherapy
Phase 2CompletedSixth Affiliated Hospital, Sun Yat-sen University422021-05-012026-07-01
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
PD-1 antibody, Chemoradiation, Albumin-Bound Paclitaxel - Esophagus Cancer, Chemoradiotherapy
Phase 2CompletedCancer Institute and Hospital, Chinese Academy of Medical Sciences352020-10-012025-05-30
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
Anlotinib plus Sintilimab - Colorectal Cancer, Immunotherapy
Phase 2CompletedShanghai Changzheng Hospital302020-06-012024-04-23
Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma
camrelizumab, Paclitaxel for injection (albumin-bound), Cisplatin - Esophageal Squamous Cell Carcinoma, Immunotherapy
Phase 2CompletedGuangzhou Institute of Respiratory Disease562020-01-172021-02-02
Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy
Dacarbazine (DTIC) - Immunotherapy
Phase 2CompletedUniversity of Erlangen-Nürnberg Medical School382020-01-132026-02-10
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy
A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel - Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
Phase 2CompletedLei Li342019-12-062022-03-15
Omalizumab to Accelerate a Symptom-driven Multi-food OIT
Omalizumab 16mg/kg, Omalizumab 8mg/kg, Placebo - Food IgE-mediated Allergy, Immunotherapy
Phase 2CompletedPhilippe Bégin902019-11-112026-11-04
Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG
Part A) Healthy subjects, Part B) Advanced solid tumor - Immunotherapy
Phase 1 / Phase 2CompletedAjou University School of Medicine242018-11-062021-07-06
The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy
Anlotinib in combination with Immune checkpoint inhibitors - NSCLC, Angiogenesis
Phase 1 / Phase 2CompletedThe Affiliated Hospital of Qingdao University302018-06-012020-12-17
MAPS & ITEC Cohorts: 6-8 Years Follow-up
House dust-mite SLIT, Normal saline - Immunotherapy, Allergy and Immunology
Phase 2CompletedUniversity of Southampton2632017-09-152021-10-04
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma
Nivolumab, Ipilimumab - Immunotherapy, Head and Neck Neoplasms
Phase 1 / Phase 2CompletedThe Netherlands Cancer Institute332017-02-282023-10-23

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Carcinoma, Non-Small-Cell Lung (2)  ·  Colorectal Neoplasms (2)  ·  Melanoma (2)  ·  Neoplasms (2)  ·  Rectal Neoplasms (2)  ·  Asthma (1)  ·  Brain Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Esophageal Squamous Cell Carcinoma (1)  ·  Head and Neck Neoplasms (1)  ·  Hypersensitivity (1)  ·  Prostatic Neoplasms (1)  ·  Prostatic Neoplasms, Castration-Resistant (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Stomach Neoplasms (1)

Broader conditions

Neoplasms by Site (15)  ·  Neoplasms (14)  ·  Digestive System Diseases (6)  ·  Digestive System Neoplasms (6)  ·  Gastrointestinal Diseases (6)  ·  Gastrointestinal Neoplasms (6)  ·  Intestinal Diseases (4)  ·  Intestinal Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Rectal Diseases (4)  ·  Genital Diseases (3)  ·  Head and Neck Neoplasms (3)  ·  Lung Diseases (3)  ·  Respiratory Tract Diseases (3)  ·  Urogenital Diseases (3)

Interventions

anlotinib (3)  ·  tislelizumab (3)  ·  Albumin-Bound Paclitaxel (2)  ·  Cisplatin (2)  ·  Radiotherapy (2)  ·  Afatinib (1)  ·  Bevacizumab (1)  ·  Chemoradiotherapy (1)  ·  Dacarbazine (1)  ·  Docetaxel (1)  ·  Drug Therapy (1)  ·  Immune Checkpoint Inhibitors (1)  ·  Immunotherapy (1)  ·  Injections (1)  ·  Ipilimumab (1)

Sponsors

Ajou University School of Medicine (1)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)  ·  Changhai Hospital (1)  ·  Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1)  ·  Dr. Ronnie Shapira (1)  ·  Fudan University (1)  ·  Fujian Cancer Hospital (1)  ·  Guangzhou Institute of Respiratory Disease (1)  ·  Lei Li (1)  ·  MacroGenics (1)  ·  Nantes University Hospital (1)  ·  Philippe Bégin (1)  ·  Radboud University Medical Center (1)  ·  Second Affiliated Hospital of Nanchang University (1)  ·  Shanghai Changzheng Hospital (1)

Countries

China (13)  ·  France (2)  ·  Netherlands (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Georgia (1)  ·  Germany (1)  ·  Israel (1)  ·  Poland (1)  ·  Puerto Rico (1)  ·  South Korea (1)  ·  Spain (1)

Top investigators

Dong-Ho Nahm (1)  ·  Fred Witjes, MD PhD (1)  ·  Graham Roberts, Prof (1)  ·  Jolanda IM de Vries, PhD (1)  ·  Jun Huang, MD (1)  ·  Lei Li, M.D. (1)  ·  Lotje Zuur, MD, PhD (1)  ·  Pepi Pencheva, M.D. (1)  ·  Ronnie Shapira-Frommer, Dr (1)  ·  Winald R Gerritsen, MD PhD (1)

Results publications

PMID 25539810, PMID 25846669, PMID 26073754, PMID 27389519, PMID 28159490, PMID 28734760, PMID 29398921, PMID 31727154, PMID 32328115, PMID 32358699, PMID 32514802, PMID 32698790, PMID 32824490, PMID 33189037, PMID 33194595, PMID 33282742, PMID 33607964, PMID 34937871, PMID 34957526, PMID 35665739, PMID 37709314, PMID 40954146, PMID 41894181, PMID 42114951